Infectious Diseases II

1314. https://doi.org/10.1001/jama.2022.17034

Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko

WC. Cefepime therapy for monomicrobial bacteremia

caused by cefepime-susceptible extended-spectrum

beta-lactamase-producing

Enterobacteriaceae:

MIC

matters. Clin Infect Dis. 2013;56(4):488-495. https://doi.

org/10.1093/cid/cis916

Liu C, Bayer A, Cosgrove SE, et al. Clinical practice

guidelines by the Infectious Diseases Society of America

for the treatment of methicillin-resistant Staphylococcus

aureus infections in adults and children: executive sum-

mary. Clin Infect Dis. 2011;52(3):285-292. https://doi.

org/10.1093/cid/cir034

Motsch J, Murta de Oliveira C, Stus V, et al. RESTORE-

IMI 1: a multicenter, randomized, double-blind trial

comparing efficacy and safety of imipenem/relebactam

vs colistin plus imipenem in patients with imipenem-

nonsusceptible bacterial infections. Clin Infect Dis.

2020;70(9):1799-1808. https://doi.org/10.1093/cid/ciz530

Nation RL, Garonzik SM, Thamlikitkul V, et al.

Dosing guidance for intravenous colistin in critically-ill

patients. Clin Infect Dis. 2017;64(5):565-571. https://doi.

org/10.1093/cid/ciw839

Prasad P, Sun J, Danner RL, Natanson C. Excess deaths

associated with tigecycline after approval based on non-

inferiority trials. Clin Infect Dis. 2012;54(12):1699-1709.

https://doi.org/10.1093/cid/cis270

Prokocimer P, De Anda C, Fang E, Mehra P, Das

A. Tedizolid phosphate vs linezolid for treat-

ment of acute bacterial skin and skin structure

infections:

the

ESTABLISH-1

randomized

trial.

2013;309(6):559-569.

https://doi.org/10.1001/

jama.2013.241

Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment

outcome

of

bacteremia

due

to

KPC-producing

Klebsiella pneumoniae: superiority of combination

antimicrobial regimens. Antimicrob Agents Chemother.

2012;56(4):2108-2113.

https://doi.org/10.1128/

aac.06268-11

Retamar P, López-Cerero L, Muniain MA, et al;

ESBL-REIPI/GEIH Group. Impact of the MIC of

piperacillin-tazobactam on the outcome of patients

with

bacteremia

due

to

extended-spectrum-β-

lactamase-producing Escherichia coli. Antimicrob

Agents Chemother. 2013;57(7):3402-3404. https://doi.

org/10.1128/aac.00135-13

Rodríguez-Baño J, Navarro MD, Retamar P, et al;

Extended-Spectrum Beta-Lactamases–Red Española de

Investigación en Patología Infecciosa/Grupo de Estudio

de Infección Hospitalaria Group. β-Lactam/β-lactam

inhibitor combinations for the treatment of bactere-

mia due to extended-spectrum β-lactamase-producing

Escherichia coli: a post hoc analysis of prospective

cohorts. Clin Infect Dis. 2012;54(2):167-174. https://doi.

org/10.1093/cid/cir790

Rybak MJ. Resistance to antimicrobial agents: an update.

doi.org/10.1592/phco.24.18.203s.52236

Rybak MJ, Le J, Lodise TP, et al. Therapeutic moni-

toring of vancomycin for serious methicillin-resistant

Staphylococcus aureus infections: a revised consensus

guideline and review by the American Society of Health-

System Pharmacists, the Infectious Diseases Society of

America, the Pediatric Infectious Diseases Society, and

Health Syst Pharm. 2020;77(11):835-864. https://doi.

org/10.1093/ajhp/zxaa036

Solomkin J, Evans D, Slepavicius A, et al. Assessing the

efficacy and safety of eravacycline vs ertapenem in com-

plicated intra-abdominal infections in the investigating

gram-negative infections treated with eravacycline

Surg.

2017;152(3):224-232.

https://doi.org/10.1001/

jamasurg.2016.4237

Tamma PD, Girdwood SC, Gopaul R, et al. The use of

cefepime for treating AmpC β-lactamase-producing

Enterobacteriaceae. Clin Infect Dis. 2013;57(6):781-788.

https://doi.org/10.1093/cid/cit395

Tamma PD, Heil EL, Justo JA, et al. IDSA 2024 guidance

on the treatment of antimicrobial resistant gram-negative

infections. Clin Infect Dis. 2024 Aug 7:ciae403. https://

doi.org/10.1093/cid/ciae403

Tasina E, Haidich AB, Kokkali S, Arvanitidou M.

Efficacy and safety of tigecycline for the treatment of

Dis.

2011;11(11):834-844.

https://doi.org/10.1016/

s1473-3099(11)70177-3

Tumbarello M, Viale P, Viscoli C, et al. Predictors of

mortality in bloodstream infections caused by Klebsiella

pneumoniae carbapenemase-producing K. pneumoniae: